Effect of Anlotinib Assisted Conformal Intensity Modulated Radiotherapy and Synchronous Chemotherapy in the Clinical Treatment of Lung Cancer Patients with Brain Metastases
Objective To investigate the effect of anlotinib assisted conformal intensity modulated radiotherapy and synchronous chemotherapy in patients with brain metastasis of lung cancer.Methods The clinical data of 100 patients with brain metastasis of lung cancer who were treated in Shandong Guoxin Yiyang Group Zaozhuang Hospital from January 2021 to November 2022 were retrospectively analyzed, and they were divided into a control group and an observation group according to different treatment regimens.50 cases receiving conformal intensity modulated radiotherapy synchronous chemotherapy were taken as the control group, and 50 cases receiving anlotinib assisted conformal intensity modulated radiotherapy synchronous chemotherapy were taken as the observation group.Both groups were treated for 2 cycles.The efficacy, tumor marker levels, the occurrence of adverse reactions and the prognosis of the two groups were compared.Results The disease control rate of the observation group was 92.00%, higher than 70.00% of control group, the difference was statistically significant (P<0.05).After treatment, the levels of carcinoembryonic antigen and squamous cell carcinoma antigen in the observation group were lower than those in the control group, and the differences between the groups were statistically significant (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).The overall survival and progression-free survival of the observation group were longer than those of the control group, and the differences between the groups were statistically significant (P<0.05).Conclusion The effect of anlotinib assisted conformal intensity modulated radiotherapy and synchronous chemotherapy is satisfactory, which can reduce the levels of tumor markers and improve the prognosis of lung cancer patients with brain metastases.